These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7581101)

  • 1. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
    Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
    Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.
    Szer J; Grigg AP; Phillips GL; Sheridan WP
    Bone Marrow Transplant; 1993 Feb; 11(2):109-11. PubMed ID: 8435660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation.
    Forés R; Díez-Martin JL; Briz M; Cabrera JR; Sanjuán I; Regidor C; Garcia-Talavera J; Fernandez MN
    Bone Marrow Transplant; 1996 Mar; 17(3):439-41. PubMed ID: 8704703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term molecular remission induced by donor lymphocyte infusions for recurrent acute myeloblastic leukemia after allogeneic bone marrow transplantation.
    Imoto S; Murayama T; Gomyo H; Mizuno I; Sugimoto T; Nakagawa T; Koizumi T
    Bone Marrow Transplant; 2000 Oct; 26(7):809-10. PubMed ID: 11042667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Mehta J; Powles R; Singhal S; Tait D; Swansbury J; Treleaven J
    Bone Marrow Transplant; 1995 Jul; 16(1):133-7. PubMed ID: 7581113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
    Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
    Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
    Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
    Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia.
    Chiang KY; Van Rhee F; Godder K; Bridges K; Adams S; Mehta J; Henslee-Downey PJ
    Bone Marrow Transplant; 2001 Mar; 27(5):507-10. PubMed ID: 11313684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.